Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

BACKGROUND: In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we found interleukin-6 as predictive of pazopanib benefit. We evaluated the prognostic significance of candidate cytokines and angiogenic factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558688/
https://www.ncbi.nlm.nih.gov/pubmed/28683470
http://dx.doi.org/10.1038/bjc.2017.206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558688/
https://www.ncbi.nlm.nih.gov/pubmed/28683470
http://dx.doi.org/10.1038/bjc.2017.206

Ejemplares similares